Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.
Fernández-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Gascón-Giménez F, Sainz de la Maza S, Walo-Delgado PE, Maceski A, Rodríguez-Martín E, Roldán E, Villarrubia N, Saiz A, Blanco Y, Sánchez P, Carreón-Guarnizo E, Aladro Y, Brieva L, Íñiguez C, González-Suárez I, Rodríguez de Antonio LA, Masjuan J, Costa-Frossard L, Villar LM. Fernández-Velasco JI, et al. Among authors: carreon guarnizo e. Neurol Neuroimmunol Neuroinflamm. 2021 Jan 6;8(2):e940. doi: 10.1212/NXI.0000000000000940. Print 2021 Mar 4. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33408167 Free PMC article.
Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, Meca Lallana V, Arocas Casañ V, Iniesta Martínez F, Olascoaga Urtaza J, Meca Lallana JE. Carreón Guarnizo E, et al. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrleng.2018.12.021. Epub 2021 Feb 26. Neurologia (Engl Ed). 2022. PMID: 35465911 Free article.
Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Fuentes Fernandez I, Hernandez-Clares R, Carreón Guarnizo E, Meca Lallana JE. Fuentes Fernandez I, et al. Among authors: carreon guarnizo e. Mult Scler Relat Disord. 2017 Aug;16:22-23. doi: 10.1016/j.msard.2017.06.001. Epub 2017 Jun 6. Mult Scler Relat Disord. 2017. PMID: 28755680
Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
Mutukula N, Man Z, Takahashi Y, Iniesta Martinez F, Morales M, Carreon-Guarnizo E, Hernandez Clares R, Garcia-Bernal D, Martinez Martinez L, Lajara J, Nuñez Delicado E, Meca Lallana JE, Izpisua Belmonte JC. Mutukula N, et al. Among authors: carreon guarnizo e. Stem Cell Res. 2021 May;53:102319. doi: 10.1016/j.scr.2021.102319. Epub 2021 Apr 15. Stem Cell Res. 2021. PMID: 33894548 Free article.
[Oral treatments in multiple sclerosis].
Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Meca-Lallana JE, et al. Med Clin (Barc). 2014 Dec;143 Suppl 3:23-9. doi: 10.1016/S0025-7753(15)30006-3. Med Clin (Barc). 2014. PMID: 25732946 Review. Spanish.
Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martinez F, Cabrera-Maqueda JM, León-Hernández A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Fuentes-Rumí L, et al. Among authors: carreon guarnizo e. Mult Scler Relat Disord. 2020 Sep;44:102311. doi: 10.1016/j.msard.2020.102311. Epub 2020 Jun 20. Mult Scler Relat Disord. 2020. PMID: 32593958
Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, Meca Lallana V, Arocas Casañ V, Iniesta Martínez F, Olascoaga Urtaza J, Meca Lallana JE. Carreón Guarnizo E, et al. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrl.2018.12.013. Epub 2019 Mar 28. Neurologia (Engl Ed). 2022. PMID: 30928236 Free article. English, Spanish.
15 results